Cellipont Bioservices and CellVax Therapeutics Expand Partnership to Advance cGMP Manufacturing of Personalized Immunotherapy FK-GI101 for GI Cancers
- CellVax Therapeutics
- Jul 31
- 1 min read
"Expanding our partnership with Cellipont is a critical step in scaling our personalized immunotherapy platform. Their operational excellence and shared commitment to innovation make them the ideal partner as we advance FK-GI101 into the clinic. With their support, we are accelerating our efforts to deliver targeted, patient-derived treatments to those facing some of the most difficult-to-treat cancers," said Fernando Kreutz, Chief Executive Officer at CellVax Therapeutics.
Click to access.